VISION (NCT03511664) was an international, open-label study of 177Lu-PSMA-617 in adults with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) previously treated with ≥ 1 androgen receptor pathway inhibitor and 1–2 taxane regimens. In this interview, Scott T. Tagawa, MD, MS, Weill Cornell Medicine, New York, NY, presents findings of a subgroup analysis assessing adverse event incidence by exposure to 177Lu-PSMA-617. Over 50% of patients with mCRPC received 5–6 cycles of 177Lu-PSMA-617. For cycles 1–5, treatment-emergent adverse events (TEAEs) occurred at every cycle, with similar frequency. More TEAEs were observed in cycle 6, reflecting its longer median duration than other cycles. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.